Management Team
Experienced and accomplished team of leaders
with proven track record
Our management team members include:
-
Dr. Adi Hoess - Chief Executive Officer - Ph.D.
Dr Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 leads the company as CEO. He has more than 18 years professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and CEO of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the M&A process of Jerini AG with Shire. From 2000 – 2002 Dr. Hoess was General Manager and VP of the Molecular Medicine Division at Carl-Zeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, VP of Licensing and BD.
Dr. Hoess received his PhD in chemistry and biochemistry from the University of Munich in 1991, and he also received an M.D. from the Technical University (TU) of Munich in 1997. From 1991 until 1993 Dr Hoess work as a post doc at the Dana-Faber Cancer Institute at the Harvard Medical School in Boston, USA.
Last Update: September 13, 2011
-
Dr. Rolf H. Günther - Chief Operating Officer - MD, Ph.D.
Dr. Günther has over 21 years of pharmaceutical industry experience with an extensive background in drug development, biologics, and specialty pharmaceuticals. He has held senior positions in R&D, strategy, commercial operations and general management.
Before joining Affimed in 2004, he was Vice President and General Manager of the Critical Care business unit of Aventis Behring, one of the world’s leading companies specializing in the business of plasma products. He joined Aventis Behring as Vice President of Global Clinical Research and Development in 1996, where he was responsible for successful drug approvals in the US and Europe, and became acting head of worldwide R&D in 2001.
Dr. Günther received his MD and PhD in Physical Chemistry from the University of Mainz, Germany and completed an Executive Development Program at the University of Pennsylvania’s Wharton School of Business, USA.
Last Update: September 13, 2011
-
Dr. Eugene Zhukovsky - Chief Scientific Officer - Ph.D., Biochemist
Dr. Zhukovsky joined Affimed in 2011 as Chief Scientific Officer. He has 20 years professional experience in the field of biotherapeutics research and development. Prior to Affimed, Dr. Zhukovsky was a Senior Research Fellow at Boehringer Ingelheim Pharmaceuticals where he led antibody discovery efforts directed towards inflammatory and cardiovascular diseases. From 2002 to 2009 Dr. Zhukovsky was at Xencor Inc. where he led translational research resulting in several therapeutic candidates targeting malignant and normal B cells. Prior to that he developed genomics technologies at Lynx Therapeutics and utilized phage display technology for the development of catalytic antibodies at Neurex Corporation.
Dr. Zhukovsky received his PhD in biochemistry from Brandeis University for studies of GPCR structure-function relationships employing the visual pigment rhodopsin. Prior to this, he completed an MS degree in bioorganic chemistry at St. Petersburg’s State University, where he developed a multi-step synthesis of a birth-control drug lead. From 1991 until 1995 Dr. Zhukovsky was a post doc at Genentech, Inc. engaged in quantitative studies of the contribution of secondary structural elements to global protein stability.
Last Update: December 31, 2011
-
Dr. Florian Fischer - Chief Financial Officer - Ph.D., MBA (Dipl.-Kfm.)
Dr. Fischer joined Affimed in 2005 as CFO. He has a strong track record as lead advisor in a variety of transactions and financings in the life sciences and health care sector.
Dr. Fischer is founder and CEO of MedVenture Partners — a Munich based corporate finance and strategy advisory company focusing on the life sciences and health care industry. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG.
Dr. Fischer holds a graduate degree in business administration and a PhD in public health and is an active lecturer at the Odeon Center for Entrepreneurship of the Ludwig-Maximilian University, Munich.
Last Update: March 26, 2010
-
Dr. Miroslav Ravic - Chief Medical Officer - MD, Ph.D.
Dr. Ravic joined Affimed in 2006. He is a medical professional with 30 years of combined experience in clinical practice, medical science and drug development of biologics and small molecules.
Dr. Ravic has been responsible for almost 100 clinical trials (Phase I – IV). He acts as Managing Director of Pharma Integra Limited, a London-based Biotechnology consultancy, and was Chief Clinical Officer at Antisoma, where he was responsible for the design and implementation of the global program of clinical trials on anti-cancer drugs.
Prior to Antisoma, Dr. Ravic was European Head of Clinical Research and Development at the Japanese company Eisai. Before joining Eisai, he worked at Boehringer Ingelheim and held various academic and clinical positions.
Last Update: March 26, 2010